Prevalence
of Hepatitis C Virus among blood donors in Blood Bank of Jhalawar
Hospital & Medical College Society, Jhalawar Rajasthan
Manish Kumar1, Madan Y.2
1Dr.
Manish Kumar, Dr. Yogendra Madan, both authors are Assistant Professor,
Department of Pathology, Jhalawar Medical College, Jhalawar, Rajasthan,
India.
Corresponding Author: Dr. Yogendra Madan, 4C-15, Talwandi, Kota, Rajasthan, India. E-mail: ymadan78@gmail.com
Abstract
Introduction: Hepatitis
C infection continue to be a threat to safe transfusion practices. This
study aims to determine the prevalence of Hepatitis- C virus (HCV)
among voluntary and replacement blood donors in Blood Bank of
Jhalawar Hospital & Medical College Society, Jhalawar, Rajasthan. Material and Methods: A retrospective review of donors record covering the period between Jan 2017 to Dec 2017 at Jhalawar Hospital & Medical College Society, Jhalawar, Rajasthan.
The blood collections were taken from the voluntary donors at total 69
blood donation camp and as well as from replacement donors and
voluntary donors at blood bank. The blood samples were then obtained by
standard procedures of venepuncture. Total 16495 blood donors screened
over the period of one year. Antibodies to Hepatitis C virus in
serum/plasma is detected by rapid test kit.Results: 34 out of 16495 donor population were positive for Hepatitis C (Prevalence 0.2%). Conclusion: Replacement
donors were higher prevalence than the voluntary donors. So, the
present study concludes that motivating voluntary blood donors by
conducting voluntary blood donation camp is the most effective way of
ensuring adequate supplies of safe blood and blood components for
transfusion.
Keywords: Blood donors, HCV, Replacement donors, Voluntary donors
Author Corrected: 4th March 2019 Accepted for Publication: 7th March 2019
Introduction
Blood
donation is the most important and essential part of blood transfusion
services, usually donated voluntarily or in the form of replacement.
Millions of lives are saved each year through blood transfusions, who
have lost large volumes of blood from serious accidents, major Surgical
Operation, Cancer patients requiring therapy, women with haemorrhage at
childbirth,patients of hereditary disorders like Haemophilia and
Thalassaemia, Severe burn victims as well as for individuals who have
symptomatic anemia from medical or hematologic conditions or cancers.
Blood
transfusion carries the risk of transmitting major infections such as
hepatitis, HIV, syphilis, and malaria. In minority cases, viral
infections such as cytomegalovirus, herpes virus, and
Epstein–Barr virus along with toxoplasmosis and brucellosis may
be transmitted [1]. Therefore, Blood banks are obligated to provide
adequate and safe blood to the community.In India, it is mandatory to
test every unit of blood collected for hepatitis B,hepatitis C, HIV,
syphilis and malaria [2]. If donors test positive to any of the five
infections, their blood is discarded.
Hepatitis
C virus (HCV) is a hepatotropic virus which was first discovered in
1989 as an important cause of transfusion associated hepatitis
(“non-A, non-B hepatitis” or NANBH). It produces a slowly
progressive liver disease, namely hepatitis, cirrhosis, and
hepatocellular carcinoma (HCC). It is the most common cause of chronic
hepatitis worldwide [3]. It is affecting over 170 million people (3%)
world over. More than 3 millionpeople are affected annually [3]. HCV
belonging to Flaviviridae family and genus Hepacivirus. The genome of
HCV is a single-stranded, positive-sense RNA molecule (++ss RNA) of
approximately 9.6 kb in length. composed of a long open reading frame
(ORF) flanked by untranslated regions (UTR's) at both the ends. The
precursor is cleaved into at least 10 different proteins: the
structural proteins: Core, E1, E2, and p7; as well as the
non-structural (NS) proteins: NS2, NS3, NS4A, NS4B, NS5A, and NS5B. An
important feature of the HCV genome is its high degree of genetic
variability. The E1 and E2 regions are the most variable, while the
5’UTR and terminal segment of the 3’UTR are highly
conserved. HCV has a high propensity for establishing chronic infection
[4]. The high-risk populations for HCV infection include injectable
drug users (IDU), blood transfusion recipients, sexually promiscuous
individuals, haemodialysis patients, HIV positive persons, kidney
transplant recipients and prisoners. Among all these, the IDU are
highest in number, and this is the primary mode of HCV transmission in
developed countries. Though the transfusion of blood and blood products
was a leading cause of transmission of HCV, after the introduction of
screening of blood units for HCV in blood banks in 1990, such a
transmission has decreased in most of the developed countries.
Unfortunately, the incidence of transfusion related hepatitis C is
still higher in developing countries like India [5].
The
HCV antigen is of core variety. The incubation period is 50–150
days. HCV spreads through blood, sexual activity when mixed with
infected blood, and through the placenta. Using used needles during
intravenous drug abuse and in unsafe healthcare setups are major risk
factors. No vaccine is available against HCV [3].
Because
of genomic instability and the antigenic variability have seriously
hampered the efforts which were made for developing an HCV vaccine. The
present study was conducted to determine the prevalence of HCV
antibodies amongblood donors at Blood Bank of Jhalawar Hospital& Medical College Society, Jhalawar, Rajasthan.
Material & Methods
Type of study: Retrospective study
Place and Duration of study: Blood
Bank, Jhalawar hospital &medical college society, Jhalawar,
Rajasthan covering the period between Jan 2017 to Dec 2017.
Sampling Methods:
All records including TTI records, donor registers, completely filled
donor forms, whichincluded the type of donation (voluntary/
replacement), the patient’s details, pre-donation questionnaire,
counselling details and medical examination findings available for each
case were analysed. The samplesfrom all blood donations were screened
for HIV 1-2, HBsAg, HCV, syphilis and malaria.Antibodies to Hepatitis C virus in serum/plasmais detected by rapid test kit.
Statistical Methods: All Data were collected for HCV and analysed in percentage
Result
Out
of the 16495 blood donors, 5013 were voluntary donors and 11482 were
replacement donors. Maximum blood donors were Rh positive. There was a
higher rate of male blood donation than females.
Totally, 2.25% (n = 371) bags were positive for transfusion transmitted infections (TTI) out of 16495 donors. Prevalence
of Hepatitis B is highest 1.88 % (311 donors) followed by infected with
HCV 0.20% (34 donors), HIV 0.10% (17 donors), malaria 0.03% (5 donors)
and syhlilis 0.024 % (4 donors) Table 1. Hepatitis B was the leading
cause among the TTI 83.82% followed HCV 9.16% and HIV 4.58% (Table 2).
Table-1: Various TTI among total blood donors.
Transfusion transmitted infections |
Voluntary donors(5013) |
Replacement donors(11486) |
Total(voluntary +Replacement) (16495) |
1.Hepatitis C |
03 |
31 |
34 |
2.Hepatitis B |
109 |
202 |
311 |
3.HIV |
03 |
14 |
17 |
4.Syphilis |
0 |
4 |
4 |
5.Malaria |
0 |
5 |
5 |
Table-2: Percentage of various infections in total TTI
Transfusion transmitted infections |
% of total TTI |
Hepatitis C |
9.16% |
Hepatitis B |
83.82% |
HIV |
4.58% |
Syphilis |
1.078% |
Malaria |
1.34% |
34
out of 16495 donor population were positive for anti HCV. (3 voluntary
donors and 31 were replacement donors). There was high prevalence of
Hepatitis C in replacement donors (0.269%) compare to voluntary donors
(0.0598%).
Discussion
Blood
transfusion services are an integral part of health care system, which
potentially saves lots of lives every day. Over one lakh people get
infected by the HCV virus every year in India. According to the
Indian National Association for the Study of the Liver, nearly 12.5
million Indians are suffering from the Hepatitis C disease, with
the death rate exceeding over one lakh. Hepatitis C has increasingly
been found to be a significant aetiological agent which causes liver
disease in India. Which could lead to chronic hepatitis, cirrhosis, and
even hepatocellular carcinoma [21]. The Hepatitis C infection is one of
the transfusion transmissible infections and the principal
etiologic agent of post-transfusion hepatitis.hence, it is mandatory to
test all the blood donors for its presence. To ensure the transfusion
of safe blood to the recipient, not only a mandatory screening of such
infection markers is necessary, but it is also important to study the
prevalence and the risk factors of the HCV infection among the donor
population.
The
virus is distributed worldwide with prevalence varying from 0.2% up to
40% in different countries. Higher HCV prevalence were reported in
Southeast Asian countries, including India (1.5%), Malaysia (2.3%),
Philippines (2.3%), Pakistan (8.1%), and in equatorial Africa (6.5%),
as high as 20% in Egypt [6].
In
the present retrospective study, we evaluated the seroprevalence
of the Hepatitis C virus among the blood donors in blood bank, Jhalawar hospital & Medical college society, Jhalawar, Rajasthan. This study gave an overview of the prevalence of the disease in the community.
Present
study showed that anti-HCV seroprevalence in the area was lower (0.2%).
it was closer to that studies were conducted by Meena et al (0.21%)[9],
Garg S et al (0.29)[8] and Bhattacharya et al(0.31%
) [17] The prevalence from the differentstudies in different regions of
India were compared in table 3. The data will help in evaluating
the seroprevalence of the Hepatitis C infection in India (TABLE 3)
Table-3: Comparison HCV seropositive prevalence of various studies with present study
S.N. |
Study |
HCV Seropositivity (%) |
1 |
Giri PA et al 2012,rural tertiary care teaching hospital in Maharastra[7] |
0.74% |
2 |
Garg S et al 2001, Rajasthan [8] |
0.29% |
3 |
Meena M et al2011, AIIMS New Delhi[9] |
0.21% |
4 |
Gupta PK et al 2006, Armed Forces[10] |
0.51% |
5 |
Narayankar SL et al 2016 Mumbai [11] |
1.49% |
6 |
kaur H et al 2012 Amritsar,Punjab[12] |
0.74% |
7 |
Poddar Net al 2012, Odisha [13] |
0.66% |
8 |
Bhawani Y et al 2010,Andhra Pradesh[14] |
0.84% |
9 |
Kochhar AK et al 2012,Southern Haryana[15] |
0.72% |
10 |
Gupta N et al 2004, Ludhiana,Punjab [16] |
1.09% |
11 |
Bhattacharya P et al 2007, Kolkata [17] |
0.31% |
12 |
Chandra T et al 2009, Lucknow [18] |
0.85 % |
13 |
Arora D et al 2010, Haryana [19] |
1.00 % |
14 |
Thakral B et al 2006, PGI, Chandigarh [20], |
0.44% |
15 |
Kulkarni N et al 2012, Karnataka [1] |
0.35% |
16 |
Das BK et al.2011, Kolkata [22] |
0.35% |
17 |
Present study |
0.20% |
Authors
Gupta N et al (1.09%)[10] and Narayankar SL et al(1.49%)[11] found
prevalence more than 1% of HCV among blood donors. Several studies
on voluntary and mixed (voluntary +replacement) blood donors shows a
prevalence of hepatitis below 2% in India. The reported variation in
the prevalence of anti-HCV antibodies among blood donors in different
regions of the world may be attributed to the differences in the
donation type, literacy rate and level of awareness among the blood
donors [11]. In the United States seroprevalence in HCV of blood donors
was estimated to be 0.3 percent [23]. In Greece also, a low prevalence
(0.2 to 0.4%) of HCV were reported and a similarly low rate (0.13%) was
also reported from Iran. Lower rates of anti-HCV antibodies were
reported in blood donors of Turkey (0.07%), Saudi Arabia (0.4%), Mexico
(0.84%) and Kenya (0.9%) [23]. The World Health Organization estimates
that the world-wide prevalence of HCV infection is approximately 3%
[24].
Presently
in India, donor screening for HCV infection is based mainly on
detection of specific antibody in serum. This does not detect
individuals in window period, which is much longer for HCV infection,
approximately 66 days, due to delayed antibody production [25,26].
Thus, an antibody based detection fails to diagnose the infection
during this period. However, viral particles become detectable earlier,
in approximately one week. Based on this, nucleic acid testing (NAT)
can be used as an alternative [27]. A recent report from New Delhi
showed that 38 sera from VBD were positive for HCV by NAT, while of
these 38, only 35 were positive for anti-HCV by ELISA. Relying only on
ELISA would miss few cases [28]. High costs, a greater turnover time
and a need of high technical expertise are the limiting factors in the
way of the generalized use of NAT, more so in developing countries
The
HCV positive donors should be informed about their disease, counseled
and referred to a hepatologist. They should also be permanently
deferred for future donations [20].
Conclusion
Our study result showed that (1) Blood donors in Blood Bank, Jhalawar hospital& Medical college society, Jhalawar, Rajasthan have a 0.20% prevalence of Hepatitis C(2)The
seroprevalence wasmore in replacement donors as compared to voluntary
donors.Therefore,Voluntary donations are safer as compared to
replacement donation.
So,
the present study concludes that motivating voluntary blood donors by
conducting voluntary blood donation camp is the most effective way of
ensuring adequate supplies of safe blood and blood components for
transfusion.
This
study provides reliable data on the prevalence of HCV infection among
blood donors and may be helpful in providing insight into disease
burden and opportunities for prevention.
Recommendations
1.
As no vaccine is available and as the treatment is expensive and
prolonged, with a poor success rate, strict donor selection remains a
key for primary prevention of HCV transmission.
2.
Blood camps should be increased to encourage the people for voluntary
blood donation, particularly in a developing country like India where
availability of safe blood and blood components for transfusion is main
challenge.
3.
More sensitive tests to detect anti HCV antibodies and nucleic acid
testing (NAT)for HCV is recommended to detect the infection at an
earlier stage, which will protect more recipients.
4.
Proper sterilization of medical equipment, especially syringes and
needles in healthcare settings, proper disposal of contaminated
material are highly recommended.
Contribution from authors
· Dr. Manish Kumar: Preparation of manuscript, Data collection, Data compiling, literature review, final approval.
· Dr. Yogendra Madan: Manuscript editing, literature review, final approval.
Funding: This research did not receive any specific grant from any funding agency in the public, commercial or nonprofit organizations.
Ethical approval: The study was conducted after ethical approval by the Institutional Ethics Committee.
Acknowledgement: We
are thankful to Dr. Rishi Diwan, HOD Pathology for allowing to conduct
this study and also acknowledge to Mr. Pankaj Malav, technician, Blood
Bank for supporting in data collection.
Conflict of Interest : None declared
References
How to cite this article?
Manish Kumar, Madan Y. Prevalence of Hepatitis C Virus among blood donors in Blood Bank of Jhalawar Hospital & Medical College Society, Jhalawar Rajasthan. Trop J Path Micro 2019;5(3):144-149.doi:10.17511/jopm. 2019.i3.06.